EGFR Antikörper

Produktnummer ABIN371623

Produktdetails anti-EGFR Antikörper

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Reaktivität: Human

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser EGFR Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro))

Spezifität: This antibody reacts with human EGFR (150 kDa). It reacts specifically with the EGFR but does not react with Her-2 recombinant protein.

Produktmerkmale: Synonyms: Epidermal growth factor receptor, EGF Receptor, erbB-1, c-ErbB-1, Receptor tyrosine-proteinkinase erbB-1, Proto-oncogene c-ErbB-1

Aufreinigung: Purified

Immunogen: Recombinant human EGFR.

Klon: SB41a

Isotyp: IgG2a

Anwendungsinformationen

Applikationshinweise: Western Blot: < / = 1-2 μg/mL. Immunohistochemistry (FS or cultured and Methanol-Fixed Cell Lines): 10 μg/mL
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.1 mg/mL

Buffer: 100 mM Borate buffered saline, pH 8.0 without preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

Haltbarkeit: 12 months

Details zu EGFR

Target: EGFR (Epidermal Growth Factor Receptor (EGFR))

Andere Bezeichnung: EGFR / ERBB1 (EGFR Produkte)

Synonyme: C-erb antikoerper, CG10079 antikoerper, D-EGFR antikoerper, D-Egf antikoerper, DEGFR antikoerper, DER antikoerper, DER flb antikoerper, DER/EGFR antikoerper, DER/faint little ball antikoerper, DER/top antikoerper, DER/torpedo antikoerper, DER1 antikoerper, DEgfr antikoerper, Degfr antikoerper, Der antikoerper, DmHD-33 antikoerper, Dmel\\CG10079 antikoerper, EFG-R antikoerper, EGF-R antikoerper, EGFR antikoerper, EGFr antikoerper, EGfr antikoerper, EK2-6 antikoerper, Egf antikoerper, Egf-r antikoerper, EgfR antikoerper, El antikoerper, Elp antikoerper, Elp-1 antikoerper, Elp-B1 antikoerper, Elp-B1RB1 antikoerper, HD-33 antikoerper, TOP antikoerper, Torpedo/DER antikoerper, Torpedo/Egfr antikoerper, c-erbB antikoerper, d-egf-r antikoerper, dEGFR antikoerper, dEGFR1 antikoerper, dEgfr antikoerper, der antikoerper, egfr antikoerper, flb antikoerper, l(2)05351 antikoerper, l(2)09261 antikoerper, l(2)57DEFa antikoerper, l(2)57EFa antikoerper, l(2)57Ea antikoerper, mor1 antikoerper, top antikoerper, top/DER antikoerper, top/flb antikoerper, torpedo/Egfr antikoerper, torpedo/egfr antikoerper, EGFR12 antikoerper, EGFR15 antikoerper, egfr1 antikoerper, Erbb2 antikoerper, ERBB antikoerper, ERBB1 antikoerper, HER1 antikoerper, PIG61 antikoerper, mENA antikoerper, ErbB-1 antikoerper, Errp antikoerper, 9030024J15Rik antikoerper, AI552599 antikoerper, Erbb antikoerper, Errb1 antikoerper, Wa5 antikoerper, wa-2 antikoerper, wa2 antikoerper, epidermal growth factor receptor antikoerper, Epidermal growth factor receptor antikoerper, epidermal growth factor receptor a (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) antikoerper, EGFR antikoerper, Egfr antikoerper, egfra antikoerper, egfr1 antikoerper, LOC5564544 antikoerper

Hintergrund: Epidermal growth factor receptor (EGFR) is a transmembrane receptor for epidermal growth factor (EGF). It is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB -1), HER2/c-neu (ErbB-2) Her 3 (ErbB-3 and Her 4 (ErbB-4). EGFR exists on the cell surface as inactive monomers and is activated by binding of its specific ligands, including EGF, transforming growth factor alpha (TGFalpha), or others. Upon activation, EGFR can pair with another EGFR to form an active homodimer or an EGFR may pair with another member of the ErbB receptor family, such as Her 2/c-neu, to create a heterodimer. Evidence also suggests that a cluster of active EGFR can form. (Ref.1-3) The binding of ligand stimulates the intrinsic protein-tyrosine kinase activity of EGFR which initiates a signal transduction cascade leading to DNA synthesis and cell proliferation. The kinase activity can also result in autophosphorylation of the five tyrosine residues in the C-terminal domain of EGFR. Autophosphorylation elicits downstream activation and signaling events of other proteins that are often distinct from those activated by the kinase domain of EGFR. Such proteins modulate phenotypes such as cell migration, adhesion, and proliferation. The kinase domain of EGFR can also cross-phosphorylate tyrosine residues of other receptors it is aggregated with, and can itself be activated in this manner. Mutations that lead to EGFR overexpression or overactivity have been associated with many common solid human squamous cell carcinomas including breast, brain, bladder, lung, gastric, head and neck, esophagus, cervix, vulva, ovary, and endometrium. (Ref.4-7) EGFR and ErbB -2 are particularly important in breast cancer because increased production or activation has been associated with poor prognosis. Tumor aggressiveness and patient outcome can be directly correlated to the production levels. Inhibitors of EGFR represent an emerging new class of anti-cancer drugs that target the underlying molecular changes involving oncogenes and tumor suppressor genes, genes that play critical roles in the conversion of normal cells into a cancerous state.Synonyms: EGF Receptor, Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, c-ErbB-1, erbB-1

Gen-ID: 1956

UniProt: P00533

Pathways: NF-kappaB Signalweg, RTK Signalweg, Fc-epsilon Rezeptor Signalübertragung, EGFR Signaling Pathway, Neurotrophin Signalübertragung, Stem Cell Maintenance, Hepatitis C, Positive Regulation of Response to DNA Damage Stimulus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation, S100 Proteine